Infinity Pharmaceuticals

Chemical genomics-based drug discovery platform

Infinity is a clinical-stage company focused on developing new medicines for the treatment of cancer.

CEO  Adelene Q. Perkins

Advent Contact  Shahzad Malik

Advent invested in 2002. Infinity listed in 2009 (NASDAQ:INFI).
Exited Investments
26 October 2010 in Infinity, Press Release

Infinity announces that Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Ltd. Exercise Rights to Develop and Commercialize Infinity’s FAAH Pain Program Worldwide

Press Release.   Decision Demonstrates Strength of Alliance and Underscores Complementary Capabilities of the Partners   CAMBRIDGE, Mass., -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that Purdue Pharmaceutical Products L.P.…
Read More
10 October 2010 in Infinity, Press Release

Infinity Announces Promising Phase 1 Data of IPI-926 in Patients With Advanced or Metastatic Solid Tumors

Press Release.   First Demonstration of Clinical Activity of IPI-926 Observed in Patients With Basal Cell Carcinoma   MILAN, Italy -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced promising preliminary results…
Read More
21 November 2008 in Infinity, Press Release

Infinity Pharmaceuticals strikes major alliance to fully fund promising pipeline

Press Release.   Infinity Announces Global Strategic Alliance With Purdue Pharma and Mundipharma Encompassing Infinity's Early Clinical and Discovery Programs Infinity Retains All U.S. Rights; Mundipharma Receives Ex-U.S. Commercialization Rights…
Read More